Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology

January 31, 2011 By Bio-Medicine.Org

BLUE BELL, Pa., Jan. 31, 2011 /PRNewswire/ — Inovio
Pharmaceuticals, Inc. (NYSE Amex:
INO
), a leader in the development of therapeutic and preventive
vaccines against cancers and infectious diseases, announced today
the regulatory approval of a Phase 2 clinical trial (WIN Trial) to
treat leukemia utilizing Inovio’s new ELGEN 1000 automated vaccine
delivery device. This open-label, multi-center clinical trial being
run by the University of Southampton is evaluating a DNA vaccine to
treat chronic myeloid leukemia and acute myeloid leukemia.
Financial support for the trial is being provided by the UK
research charity Leukaemia and Lymphoma Research (LLR) and by the
Efficacy and Mechanisms Evaluation (EME) programme (which is funded
by the UK Medical Research Council and managed by the UK National
Institute for Health Research). The DNA vaccine was developed at
the University of Southampton with funding from LLR and the charity
Cancer Research UK.

(Logo:  http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

Leukemia is a cancer of the bone marrow and blood that accounts
for at least 300,000 new cases and 222,000 deaths worldwide each
year – a very high death rate. Wilms’ Tumor gene 1 (WT1) is highly
associated with these types of cancer, which led the University of
Southampton to design its leukemia DNA vaccine to target this
antigen. Preclinical data from mice showed strong induction of
antigen-specific CD8+ T cells and the ability to kill human tumor
cells expressing WT1. There have been several prior clinical
studies in humans using parts of the WT1 gene, notably as peptide
vaccine candidates, demonstrating the production of modest levels
of CD8+ T-cell responses and measurable clinical responses,
although both effects were transient. This will be the first study
to combine DNA vaccination wit

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies
Biotronik
FDA approves Biotronik’s programmer for implanted cardiac rhythm management devices

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech